Automated literature reviews have become an increasingly important approach to managing the growing volume of scientific and clinical data. For medical device manufacturers operating under frameworks such as the EU MDR and IVDR, literature review is not a one-time activity, but an ongoing process that supports clinical evaluation, post-market surveillance (PMS), and post-market clinical follow-up (PMCF).
Traditionally, literature reviews have been resource-intensive, requiring significant time for searching, screening, and documentation. In response, automated literature review tools have emerged to support key aspects of this process, with the aim of improving efficiency, consistency, and scalability.
However, while automation can streamline workflows, its value within a regulatory context depends on how it is applied. This raises an important question: What is the true return on investment (ROI) of automated literature review for manufacturers operating under increasingly demanding regulatory requirements?
This article examines the balance between the efficiencies gained through automation and the continued need for critical human oversight in regulatory decision-making.
What Is an Automated Literature Review?
An automated literature review uses software tools to support the key stages of the review process. These platforms are designed to assist with tasks such as searching across multiple databases, removing duplicate records, screening abstracts and full texts, and organising or tagging relevant studies. Many of these tools are built on artificial intelligence (AI), machine learning, and natural language processing (NLP), which allow them to handle large volumes of data more efficiently.
Depending on the platform, automation may also extend to features such as AI-assisted screening, structured data extraction, and the generation of outputs aligned with reporting frameworks like PRISMA. These capabilities can help streamline workflows and improve the consistency of documentation across the review process.
Importantly, automation is intended to complement, rather than replace, critical appraisal. While these tools can significantly improve efficiency, expert input remains essential for interpreting findings, assessing clinical relevance, and ensuring that conclusions are appropriate within a regulatory context.
Traditional vs Automated Literature Review
Literature reviews in regulatory contexts have traditionally been conducted using manual processes, with reviewers responsible for searching databases, screening studies, removing duplicates, and documenting findings. While this approach allows for detailed evaluation and contextual understanding, it is often time-intensive and may introduce variability depending on the reviewer’s experience and methodology.
Automated literature review tools are designed to support these processes by streamlining repetitive tasks such as database searching, duplicate removal, and study screening. By applying structured workflows, these tools can improve efficiency and enable the handling of larger volumes of literature within shorter timeframes.
However, the distinction between manual and automated approaches is not simply one of replacement, but of function. Manual review remains central to the interpretation of clinical evidence, while automation is primarily used to enhance efficiency and consistency in data handling.
In practice, the differences between manual and automated literature reviews can be summarised as follows:
While automation can significantly improve efficiency and standardisation, it does not replace the need for expert evaluation. In regulatory settings, the interpretation of evidence remains a critical step that requires clinical and methodological judgement.
Inclusion and Exclusion Criteria
Defining clear inclusion and exclusion criteria is fundamental to the integrity of any literature search protocol for medical devices. These criteria act as filters, ensuring that the literature review focuses on studies that are both relevant and of high quality, directly supporting the clinical evaluation process.
Inclusion criteria should be explicitly documented and may encompass factors such as study design (e.g., randomized controlled trials, observational studies), patient population characteristics, intervention types, and specific outcome measures. The use of the PICO framework—Population, Intervention, Comparator, Outcome—can help structure the research question and identify relevant search terms, making the search strategy more targeted and effective.
Exclusion criteria are equally important, as they help eliminate studies that do not meet the predefined standards. This might include studies with a high risk of bias, those not addressing the research question, or publications outside the defined patient population or device indication. By applying these criteria consistently, manufacturers can ensure that the literature review remains focused on clinically relevant and reliable evidence.
A transparent approach to inclusion and exclusion criteria not only strengthens the credibility of the literature review but also facilitates regulatory review by providing a clear rationale for the selection and exclusion of studies. This process is essential for building a robust evidence base that supports the safety and performance claims of the device in clinical evaluation and regulatory submissions.
Understanding ROI in Automated Literature Review and Where Automation Delivers Value
In the context of an automated literature review, return on investment (ROI) extends beyond direct financial savings. While reductions in manual workload and associated costs are important, the value of automation in regulatory settings is more appropriately assessed in terms of efficiency, quality, and compliance. These returns are best understood by examining where automation delivers practical value across the literature review process.
Automated literature review tools can provide measurable value across several stages of the review process, particularly when applied to repetitive and resource-intensive tasks. While the extent of these benefits may vary depending on the tool and context, several key areas of value are consistently observed.
Efficiency and Time Savings
One of the most immediate benefits of automation is the reduction in time required for literature searching and screening. Automated tools can process large volumes of records more rapidly than manual workflows, particularly during title and abstract screening stages. This is especially relevant for manufacturers managing extensive datasets or conducting ongoing activities such as periodic literature updates. For example, in large-scale systematic reviews, automated screening tools may reduce the number of records requiring manual review by prioritising studies based on relevance. This can significantly decrease reviewer workload, particularly in early screening phases.
Cost Implications
Reducing manual effort on routine tasks lowers overall resource expenditure over time. Although software tools introduce additional costs, these may be offset by reduced reliance on labour-intensive processes, particularly in large or ongoing review programmes.
Consistency and Reproducibility
Automated workflows can support greater consistency in how literature reviews are conducted and documented. Standardised processes for screening, tagging, and data handling may reduce variability between reviewers and improve the reproducibility of results—an important consideration in regulatory environments.
Support for Regulatory Documentation
Automation supports the generation of structured outputs aligned with reporting frameworks such as PRISMA. The ability to maintain audit trails and track decision-making processes supports transparency and inspection readiness, particularly in the context of clinical evaluation, PMS, and PMCF activities. In practice, this may include automated generation of PRISMA flow diagrams or structured evidence tables, which can enhance transparency during audits and regulatory submissions.
Importantly, the overall return is not determined by automation alone, but by how effectively these tools are integrated into existing workflows. The value of automation therefore depends on its ability to support—not replace—expert-driven evaluation and decision-making.
Limitations and Risks
Despite the advantages associated with automation, several important limitations should be considered when applying these tools within a regulatory context. While automation can support efficiency and structure, it does not address all aspects of the literature review process.
Limited Critical Interpretation
Automated tools are not equipped to interpret clinical relevance or critically assess the quality of evidence. Determining the significance of study findings, identifying methodological limitations, and evaluating benefit–risk considerations remain dependent on expert judgement. In many cases, the challenge lies not in the volume of available data, but in how that data is interpreted and applied. Only expert reviewers can ensure the identification and interpretation of clinically relevant information and clinical investigation data, which are essential for comprehensive medical device evaluation and regulatory compliance.
For example, relevant studies may be excluded if screening thresholds are not appropriately calibrated, highlighting the need for ongoing validation by experienced reviewers.
Risk of Over-Reliance
Outputs generated by automated systems may be accepted too readily if not subject to sufficient critical review. Without appropriate oversight, there is a risk that irrelevant studies are included or that key evidence is inadvertently excluded during the screening process.
Dependence on Input Quality
The performance of automated literature review tools is closely tied to the quality of the initial search strategy and input parameters. Poorly constructed or incomplete searches can result in gaps in the evidence base, regardless of how efficient the downstream processes may be.
Lack of Contextual Nuance
Automated outputs may lack the contextual understanding required to interpret findings within a specific clinical or regulatory framework. As a result, summaries may be technically accurate but fail to fully capture the relevance or limitations of the available evidence.
Ethical and Transparency Considerations
The use of automation in literature review also introduces important considerations around transparency and accountability. In regulatory and research settings, it is essential to clearly document and, where required, disclose the role of automated tools within the review process. Maintaining an objective approach throughout the literature review process, especially when using automated tools, is critical to ensure unbiased, rigorous, and transparent identification, appraisal, and analysis of clinical evidence.
Data privacy is another key consideration, particularly when handling proprietary or sensitive information. In addition, the reliability of automated outputs should be assessed carefully, as some tools may produce incomplete or inaccurate summaries if not appropriately validated.
Maintaining transparency in how literature reviews are conducted—including the role of automation—supports both methodological integrity and regulatory credibility.
In regulatory settings, the value of a literature review lies not only in the identification of evidence but in its interpretation and application. Automation should therefore be viewed as a supporting tool, with expert oversight remaining essential to ensure that outputs are accurate, relevant, and meaningful.
Clinical Evaluation Reports
Clinical Evaluation Reports (CERs) are a pivotal element of the regulatory submission process for medical devices, serving as comprehensive documents that synthesize all available clinical evidence to demonstrate the safety and performance of the device. A key component of the CER is the systematic literature review, which must be conducted using a well-defined search protocol that includes a clear research question, detailed search strategy, and explicit inclusion and exclusion criteria.
To ensure thoroughness, the literature review within the CER should encompass multiple databases—such as PubMed, Embase, and Google Scholar—capturing a broad spectrum of published data relevant to the device. Only studies that meet the predefined inclusion and exclusion criteria should be included, ensuring that the evidence base is both robust and directly applicable to the device’s intended use.
The CER should provide a detailed analysis of the identified clinical evidence, discussing the strengths and limitations of each study and synthesizing findings to draw conclusions about the device’s safety and clinical performance. This analysis must be transparent and reproducible, aligning with regulatory expectations under the EU MDR and supporting audit readiness.
By integrating a systematic literature review into the CER, manufacturers can demonstrate a rigorous, evidence-based approach to clinical evaluation, facilitating regulatory approval and ongoing compliance. This process not only supports the initial CE mark application but also underpins post-market surveillance and continuous improvement of the device’s clinical profile.
Practical Considerations for Manufacturers
When integrating automated literature review tools into regulatory workflows, it is important to consider how and where these tools add value. While automation can improve efficiency, its impact ultimately depends on how it is implemented and monitored within the broader review process.
Where Automation Adds Value
A well-defined literature search protocol remains essential regardless of the tools used. This includes clearly documented search strings, database selection, date ranges, and inclusion/exclusion criteria;Â Â all of which should be established before the automated workflow begins and maintained as part of the audit trail. These stages benefit from increased speed and consistency, particularly when managing large volumes of data or conducting regular updates.
The Role of Expert Oversight
Despite the efficiencies offered by automation, expert input remains central to the review process. Assessing clinical relevance, interpreting study outcomes, and drawing regulatory conclusions all require clinical and methodological expertise that cannot be replicated by automated systems. For more information, visit a systematic literature review.
A Hybrid Approach in Practice
In most cases, a combined approach—where automation supports data handling and experts guide interpretation—provides the most practical and reliable solution. This allows organisations to improve efficiency while maintaining the quality and credibility of regulatory outputs.
Maintaining Methodological Rigor
The use of automation does not remove the need for a well-defined review methodology. Clear search strategies, inclusion and exclusion criteria, and robust documentation practices remain necessary to ensure that literature reviews are comprehensive, transparent, and defensible.
Ultimately, the successful use of automated literature review tools depends on aligning their capabilities with regulatory objectives, while maintaining appropriate levels of oversight and quality control.
Conclusion
Automated literature review offers clear advantages in managing the ever-increasing volume and complexity of scientific evidence. By supporting tasks such as searching, screening, and documentation, these tools can improve efficiency, consistency, and scalability within regulatory workflows.
However, the value of automation is not defined by efficiency alone. In regulatory settings, the quality of a literature review depends on the accurate interpretation and application of evidence, which remains dependent on expert judgement.
As such, the return on investment of automated literature review is best understood in the context of how these tools are applied. When combined with robust methodology and appropriate oversight, automation becomes a valuable enabler of more sustainable and effective evidence generation.
If you are evaluating how automated literature review tools could support your MDR or IVDR compliance program, or want to understand where expert oversight is most critical for your specific device, Citemeds can help. Our team works with medical device manufacturers to design and conduct literature reviews that meet regulatory expectations — combining the efficiency of structured workflows with the clinical expertise that regulatory submissions require. Get in touch to discuss your requirements.
